Cargando…

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

BACKGROUND: Cytogenetic aberrations such as deletion of chromosome 5q (del(5q)) represent key elements in routine clinical diagnostics of haematological malignancies. Currently established methods such as metaphase cytogenetics, FISH or array-based approaches have limitations due to their dependency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jann, Johann-Christoph, Nowak, Daniel, Nolte, Florian, Fey, Stephanie, Nowak, Verena, Obländer, Julia, Pressler, Jovita, Palme, Iris, Xanthopoulos, Christina, Fabarius, Alice, Platzbecker, Uwe, Giagounidis, Aristoteles, Götze, Katharina, Letsch, Anne, Haase, Detlef, Schlenk, Richard, Bug, Gesine, Lübbert, Michael, Ganser, Arnold, Germing, Ulrich, Haferlach, Claudia, Hofmann, Wolf-Karsten, Mossner, Maximilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Medical Genetics 2017
Materias:	Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574397/ https://www.ncbi.nlm.nih.gov/pubmed/28600436 http://dx.doi.org/10.1136/jmedgenet-2017-104528

Ejemplares similares

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
por: Rummelt, Christoph, et al.
Publicado: (2023)

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo
por: Jann, Johann-Christoph, et al.
Publicado: (2021)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
por: Kasprzak, A., et al.
Publicado: (2022)

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
por: Giagounidis, Aristoteles A. N., et al.
Publicado: (2006)

Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations
por: Flach, Johanna, et al.
Publicado: (2020)

Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report
por: Mitsogianni, Maria, et al.
Publicado: (2018)

Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium
por: Altrock, Eva, et al.
Publicado: (2023)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

The DAC system and associations with acute leukemias and myelodysplastic syndromes
por: Bug, Gesine, et al.
Publicado: (2010)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
por: Fenaux, Pierre, et al.
Publicado: (2018)

A young traveller presenting with typhoid fever after oral vaccination: a case report
por: Grimm, Martin, et al.
Publicado: (2013)

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS
por: Giagounidis, Aristoteles, et al.
Publicado: (2011)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE
por: van Zeeburg, Hester, et al.
Publicado: (2023)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
por: Schmitt, Nanni, et al.
Publicado: (2021)

Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series
por: Stein, Anna, et al.
Publicado: (2022)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide
por: Mährle, Thorben, et al.
Publicado: (2019)

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
por: Kubasch, Anne Sophie, et al.
Publicado: (2022)

Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS
por: Ruppenthal, Sabrina, et al.
Publicado: (2018)

Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature
por: Mitsimponas, Nikolaos, et al.
Publicado: (2017)

High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia
por: Hütter, Gero, et al.
Publicado: (2009)

Mutation Analysis of hCDC4 in AML Cells Identifies a New Intronic Polymorphism
por: Nowak, Daniel, et al.
Publicado: (2006)

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
por: Kuendgen, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7krb247vboc0a8aoe86p9fli4c